BIOMAT Database Logo BIOMAT Database Logo

Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships. 1995

R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Department of Gynecology, Centro Chimica dei Recettori C.N.R., Rome, Italy.

This study was carried out to determine the effect of 15 different natural and synthetic chalcones on the proliferation of both established and primary ovarian cancer cells expressing type II oestrogen binding sites (type II EBS). The binding affinity of chalcones for type II EBS was also tested. At concentrations from 0.1 to 10 microM, chalcones inhibited ovarian cancer cell proliferation and [3H]oestradiol ([3H]E2) binding to type II EBS. Considering the structure-related variation in IC50 (concentration resulting in a 50% inhibition of cell growth) and Di50 (concentration resulting in a 50% displacement of [3H]E2 bound to type II EBS), it appeared that the presence of an alpha-beta double bond, the hydroxylation in 3 or 2 of ring B and the absence of a prenyl group were important to both the antiproliferative and binding activity. Structure-related variations in IC50 and Di50 were significantly concordant (Fisher's exact test: P = 0.0291), suggesting that there may be a type II EBS-mediated mechanism for chalcone antiproliferative activity. Our data indicate that chalcones could be considered as potential new anticancer drugs.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002599 Chalcone An aromatic KETONE that forms the core molecule of CHALCONES. Benzalacetophenone,Benzylideneacetophenone,1,3-Diphenyl-2-Propen-1-One,Chalkone,1,3 Diphenyl 2 Propen 1 One
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Structure-activity relationships of naturally occurring and synthetic opioid tetrapeptides acting on locus coeruleus neurons.
May 1999, European journal of pharmacology,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
An update on antitumor activity of naturally occurring chalcones.
January 2013, Evidence-based complementary and alternative medicine : eCAM,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
In vitro leishmanicidal activity of naturally occurring chalcones.
March 2001, Phytotherapy research : PTR,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Structural antitumoral activity relationships of synthetic chalcones.
January 2009, International journal of molecular sciences,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
In vitro anti-proliferative effect of naturally occurring oxyprenylated chalcones.
August 2013, Natural product communications,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
January 2012, Bioorganic & medicinal chemistry,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Antinociceptive properties of chalcones. Structure-activity relationships.
October 2001, Archiv der Pharmazie,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships.
May 2007, Bioorganic & medicinal chemistry,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Structure-activity relationships of antileishmanial and antimalarial chalcones.
July 2003, Bioorganic & medicinal chemistry,
R De Vincenzo, and G Scambia, and P Benedetti Panici, and F O Ranelletti, and G Bonanno, and A Ercoli, and F Delle Monache, and F Ferrari, and M Piantelli, and S Mancuso
Opioid activity of synthetic and naturally occurring enkephalin peptides.
November 1979, Biochemical pharmacology,
Copied contents to your clipboard!